Results 201 to 210 of about 18,037 (235)
Some of the next articles are maybe not open access.
Mineralocorticoid receptor antagonists
2018Abstract Hypertension, post-myocardial infarction, and heart failure are the cardiovascular clinical syndromes where mineralocorticoid receptor antagonists (MRAs) have shown a beneficial effect. Most guidelines while recommending a MRA do not make a clear recommendation as to which MRA should be used, how doses should be titrated, or ...
Faiez Zannad, João Pedro Ferreira
openaire +1 more source
Mineralocorticoid Receptor Antagonists in Primary Aldosteronism
Current Pharmaceutical Design, 2019Background:Primary aldosteronism is the most common causes of secondary hypertension. Patients suffering from this clinical syndrome have an increased cardiovascular risk and target organ damage. Mineralocorticoid receptor antagonists are the optimal pharmaceutical option for the management of such patients.Objectives:The study aimed to assess the ...
Konstantinos, Stavropoulos +5 more
openaire +2 more sources
The renal effects of mineralocorticoid receptor antagonists
International Journal of Cardiology, 2015Beyond its well known classic effects on renal water and electrolytes metabolism, an increasing amount of experimental and clinical evidence suggests that aldosterone contributes to the pathogenesis and progression of kidney disease. The binding of aldosterone on epithelial and non-epithelial cells of the kidney induces many deleterious effects, such ...
Stefano, Bianchi +2 more
openaire +2 more sources
Mineralocorticoid Receptor Antagonists: a Comprehensive Review of Finerenone
Current Cardiology Reports, 2020We aim to review the mechanism of action and safety profile of mineralocorticoid receptor antagonists (MRAs) and discuss the differences between selective and non-selective MRAs. More specifically, finerenone is a new medication that is currently under investigation for its promising cardiovascular and nephrological effects.MRAs are well known for ...
Juan Simon, Rico-Mesa +3 more
openaire +2 more sources
Role of mineralocorticoid receptor antagonists in kidney diseases
Drug Development Research, 2020Abstract Mineralocorticoid receptor (MR) antagonists, for example, spironolactone and eplerenone, are in clinical use to treat hypertension. Increasing evidence suggests that mineralocorticoid receptor activation causes the pathogenesis and progression of chronic kidney disease. Aldosterone‐induced MR activation increases inflammation,
Vishal Patel +2 more
openaire +2 more sources
Emerging cardiovascular indications of mineralocorticoid receptor antagonists
Trends in Endocrinology & Metabolism, 2015Mineralocorticoid receptor (MR) antagonism is a well-established treatment modality for patients with hypertension, heart failure, and left ventricular systolic dysfunction (LVSD) post-myocardial infarction (MI). There are emerging data showing potential benefits of MR antagonists in other cardiovascular conditions.
Parviz, Yasir +5 more
openaire +2 more sources
Mineralocorticoid receptor antagonists in kidney transplantation
European Journal of Clinical InvestigationAbstractBackgroundThe fundamental role of the renin–angiotensin–aldosterone system in the pathophysiology of chronic kidney disease, congestive heart failure, hypertension and proteinuria is well established in pre‐clinical and clinical studies. Mineralocorticoid receptor antagonists are among the primary options for renin–angiotensin–aldosterone ...
Mehmet Kanbay +4 more
openaire +2 more sources
Mineralocorticoid receptor antagonists (MRAs)
2014Abstract The final process in the renin–angiotensin–aldosterone system (RAAS) is the production of the mineralocorticoid aldosterone in the adrenal glands. Aldosterone has an important role in the pathophysiology of heart failure, and concentrations of aldosterone are 20-fold higher in patients with HF compared to normal individuals ...
Roy S. Gardner +2 more
openaire +1 more source
Mineralocorticoid receptor antagonists—pharmacodynamics and pharmacokinetic differences
Current Opinion in Pharmacology, 2016Mineralocorticoid receptor antagonists (MRAs) are best known as potassium-sparing diuretics due to their blockade of aldosterone action in renal epithelial tissues. They are also beneficial for the treatment of heart failure, primarily due to effects in non-epithelial tissues. Currently there are only two steroidal MRAs that have been approved for use;
Jun, Yang, Morag J, Young
openaire +2 more sources
Mineralocorticoid Receptor Antagonists in Essential and Resistant Hypertension
Current Pharmaceutical Design, 2019Background: Mineralocorticoid receptor antagonists are a second-line class of antihypertensive drugs, which have been accounted for as the optimal add-on therapy in the triple algorithm for the management of resistant hypertension. Objectives: To assess the effects of mineralocorticoid receptor antagonists in the treatment of patients with ...
Konstantinos P, Imprialos +6 more
openaire +2 more sources